Akero Therapeutics Inc. (AKRO) and Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Comparing side by side

This is a contrast between Akero Therapeutics Inc. (NASDAQ:AKRO) and Fennec Pharmaceuticals Inc. (NASDAQ:FENC) based on their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Akero Therapeutics Inc. 20 0.00 8.81M -3.22 0.00
Fennec Pharmaceuticals Inc. 5 0.00 14.47M -0.57 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Akero Therapeutics Inc. and Fennec Pharmaceuticals Inc.


Table 2 provides us the return on equity, return on assets and net margins of both companies.

Net Margins Return on Equity Return on Assets
Akero Therapeutics Inc. 43,059,628.54% 0% 0%
Fennec Pharmaceuticals Inc. 276,673,040.15% -49.6% -46.5%


Akero Therapeutics Inc.’s Current Ratio and Quick Ratio are 29.4 and 29.4 respectively. The Current Ratio and Quick Ratio of its competitor Fennec Pharmaceuticals Inc. are 14 and 14 respectively. Akero Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Fennec Pharmaceuticals Inc.

Insider and Institutional Ownership

Akero Therapeutics Inc. and Fennec Pharmaceuticals Inc. has shares held by institutional investors as follows: 48.5% and 51.6%. About 17.8% of Akero Therapeutics Inc.’s share are held by insiders. Insiders Competitively, held 17.41% of Fennec Pharmaceuticals Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Akero Therapeutics Inc. 5.86% 27.17% 0% 0% 0% 32.1%
Fennec Pharmaceuticals Inc. 17.74% 20% 4.23% -28.22% -49.57% -26.65%

For the past year Akero Therapeutics Inc. has 32.1% stronger performance while Fennec Pharmaceuticals Inc. has -26.65% weaker performance.


On 5 of the 9 factors Akero Therapeutics Inc. beats Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.